First Trust Direct Indexing L.P. Increases Stock Position in Hologic, Inc. (NASDAQ:HOLX)

First Trust Direct Indexing L.P. increased its position in Hologic, Inc. (NASDAQ:HOLXFree Report) by 3.3% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 7,882 shares of the medical equipment provider’s stock after acquiring an additional 253 shares during the period. First Trust Direct Indexing L.P.’s holdings in Hologic were worth $614,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in HOLX. McGlone Suttner Wealth Management Inc. bought a new stake in Hologic in the 4th quarter worth approximately $27,000. Massmutual Trust Co. FSB ADV grew its position in shares of Hologic by 69.4% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock valued at $40,000 after acquiring an additional 227 shares during the period. Allworth Financial LP grew its position in shares of Hologic by 39.3% during the 4th quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 179 shares during the period. Mather Group LLC. bought a new stake in shares of Hologic during the 1st quarter valued at $48,000. Finally, Livforsakringsbolaget Skandia Omsesidigt grew its position in shares of Hologic by 145.3% during the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 790 shares of the medical equipment provider’s stock valued at $56,000 after acquiring an additional 468 shares during the period. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Up 0.8 %

Shares of HOLX stock opened at $74.10 on Friday. The stock has a market cap of $17.29 billion, a P/E ratio of 37.81, a PEG ratio of 2.45 and a beta of 0.99. Hologic, Inc. has a 52 week low of $64.02 and a 52 week high of $82.45. The company has a quick ratio of 3.29, a current ratio of 3.97 and a debt-to-equity ratio of 0.52. The company’s fifty day simple moving average is $74.06 and its two-hundred day simple moving average is $74.40.

Hologic (NASDAQ:HOLXGet Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $0.98 by $0.05. The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1 billion. Hologic had a net margin of 11.78% and a return on equity of 18.91%. The business’s quarterly revenue was down .8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.06 EPS. Analysts predict that Hologic, Inc. will post 4.08 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Stephens assumed coverage on shares of Hologic in a research report on Thursday, June 27th. They set an “overweight” rating and a $87.00 price objective for the company. Argus boosted their price objective on shares of Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, May 9th. JPMorgan Chase & Co. boosted their price objective on shares of Hologic from $85.00 to $91.00 and gave the company an “overweight” rating in a research report on Friday, May 3rd. Evercore ISI dropped their target price on shares of Hologic from $78.00 to $76.00 and set an “in-line” rating for the company in a report on Tuesday, July 2nd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 target price on shares of Hologic in a report on Friday, May 3rd. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Hologic currently has a consensus rating of “Moderate Buy” and a consensus price target of $85.55.

Read Our Latest Stock Analysis on Hologic

Hologic Profile

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

See Also

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.